Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deuterated 3-methylhistidine is a stable isotope-labeled derivative of the amino acid histidine in which three hydrogen atoms are replaced by deuterium. It is primarily used as a diagnostic and research tool rather than as a therapeutic drug. Upon administration, deuterated 3-methylhistidine is incorporated into muscle proteins (specifically actin and myosin) and subsequently excreted unchanged in urine. This property allows it to serve as a tracer for measuring skeletal muscle protein breakdown and turnover rates in vivo. The compound is widely used in metabolic studies to assess muscle protein catabolism by tracking its appearance in biological samples such as urine or plasma[1][2][4][5]. It does not have direct pharmacological activity but serves an important role as an internal standard or biomarker for quantifying endogenous 3-methylhistidine levels during analytical procedures[4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Deuterated 3-methylhistidine.